Gene Type Associated with Higher Risk of Celiac Disease
|
By LabMedica International staff writers Posted on 10 Jul 2014 |
Researcher have found that children born with 2 copies of a high-risk variant in a specific group of genes confers 26% chance of developing celiac disease autoimmunity (CDA), an early sign of celiac disease (CD), by age 5. They also found a higher celiac risk in Sweden than in the three other studied countries, even with the same genetic risk factors.
The Environmental Determinants of Diabetes in Youth consortium (TEDDY) is studying CD and type-1 diabetes because both are autoimmune diseases with some of the same genetic risk factors. CD (which stems from an immune reaction to gluten) occurs in just under 1% of the USA population, and is more common than type-1 diabetes. The celiac study followed 6,403 newborn children with either of two high-risk gene groups important for immune function—HLA-DR3-DQ2 or HLA-DR4-DQ8—to see who would develop CD or CDA. These genes are involved in presenting gluten to immune cells. Over five years, 291 developed CD, while another 786 developed CDA.
“By looking at the genes of the children who participated in TEDDY, we can now identify who among them is at highest risk for CD, and their parents and health care providers can monitor these children to detect the disease early,” said Beena Akolkar, PhD, project scientist for TEDDY at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; primary funder of TEDDY) of the US National Institutes of Health (NIH; Bethesda, MD, USA).
Researchers found that youth with 2 copies of HLA-DR3-DQ2 had the highest likelihood of disease development by age 5. Of this group, 26% developed CDA by age 5 and 12% developed CD. In those with 1 copy of HLA-DR3-DQ2, the risks of CDA and CD by age 5 were 11% and 3%, respectively. About 90% of CD patients carry HLA-DR3-DQ2.
Based on earlier research, lower rates of CDA and CD were expected in the USA and Germany than in Sweden. Rates of CDA in Sweden were nearly double the USA rates. However, the researchers were surprised to discover that Sweden also had higher rates of CDA and CD than Finland. “We’ve long known that Sweden has a high incidence of CD, but we don’t yet know why. TEDDY’s unique structure of having the same protocol in several countries enables us to search for factors that trigger the disease,” said the paper’s senior author Daniel Agardh, MD, PhD, of Lund University in Sweden, “By studying similarities and differences between genes and environmental factors in these countries, we hope to pinpoint risk factors for the disease.” This study will include examining how diet affects bacteria in the gut and the immune system of children with differing genetic risks.
The primary goal of TEDDY is to find the causes of type-1 diabetes—why some children with high-risk genes for type-1 diabetes go on to develop the disease while others with the same genetic risk do not. “With research networks like TEDDY, NIH is actively seeking to understand how diseases like celiac and type-1 diabetes occur and, by using genetic screening and other tools, to develop a more personalized approach to disease prevention and treatment,” said NIDDK Director Griffin P. Rodgers, MD.
The study was reported by Liu E. et al. in the New England Journal of Medicine, July 3, 2014.
Related Links:
National Institutes of Health
The Environmental Determinants of Diabetes in Youth consortium (TEDDY)
Celiac disease
The Environmental Determinants of Diabetes in Youth consortium (TEDDY) is studying CD and type-1 diabetes because both are autoimmune diseases with some of the same genetic risk factors. CD (which stems from an immune reaction to gluten) occurs in just under 1% of the USA population, and is more common than type-1 diabetes. The celiac study followed 6,403 newborn children with either of two high-risk gene groups important for immune function—HLA-DR3-DQ2 or HLA-DR4-DQ8—to see who would develop CD or CDA. These genes are involved in presenting gluten to immune cells. Over five years, 291 developed CD, while another 786 developed CDA.
“By looking at the genes of the children who participated in TEDDY, we can now identify who among them is at highest risk for CD, and their parents and health care providers can monitor these children to detect the disease early,” said Beena Akolkar, PhD, project scientist for TEDDY at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK; primary funder of TEDDY) of the US National Institutes of Health (NIH; Bethesda, MD, USA).
Researchers found that youth with 2 copies of HLA-DR3-DQ2 had the highest likelihood of disease development by age 5. Of this group, 26% developed CDA by age 5 and 12% developed CD. In those with 1 copy of HLA-DR3-DQ2, the risks of CDA and CD by age 5 were 11% and 3%, respectively. About 90% of CD patients carry HLA-DR3-DQ2.
Based on earlier research, lower rates of CDA and CD were expected in the USA and Germany than in Sweden. Rates of CDA in Sweden were nearly double the USA rates. However, the researchers were surprised to discover that Sweden also had higher rates of CDA and CD than Finland. “We’ve long known that Sweden has a high incidence of CD, but we don’t yet know why. TEDDY’s unique structure of having the same protocol in several countries enables us to search for factors that trigger the disease,” said the paper’s senior author Daniel Agardh, MD, PhD, of Lund University in Sweden, “By studying similarities and differences between genes and environmental factors in these countries, we hope to pinpoint risk factors for the disease.” This study will include examining how diet affects bacteria in the gut and the immune system of children with differing genetic risks.
The primary goal of TEDDY is to find the causes of type-1 diabetes—why some children with high-risk genes for type-1 diabetes go on to develop the disease while others with the same genetic risk do not. “With research networks like TEDDY, NIH is actively seeking to understand how diseases like celiac and type-1 diabetes occur and, by using genetic screening and other tools, to develop a more personalized approach to disease prevention and treatment,” said NIDDK Director Griffin P. Rodgers, MD.
The study was reported by Liu E. et al. in the New England Journal of Medicine, July 3, 2014.
Related Links:
National Institutes of Health
The Environmental Determinants of Diabetes in Youth consortium (TEDDY)
Celiac disease
Latest Molecular Diagnostics News
- Fully Automated Test Advances Hepatitis D Diagnosis and Monitoring
- HPV Assay Gains Expanded CE Mark for Self-Collected Vaginal Samples
- Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
- Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
- Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations
- Epigenetic Profiling Could Refine Prognosis in Acute Myeloid Leukemia
- Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis
- AI Reveals Immune Response Biomarkers Linked to Ebola Survival
- Extracellular Vesicle Marker Identifies Early Lung Adenocarcinoma and Predicts Recurrence
- WHO Adds First Bundibugyo Ebola Molecular Test to Emergency Use Listing
- Blood Test Helps Guide Post-Surgical Treatment in Metastatic Colorectal Cancer
- Study Supports Earlier Genetic Testing for Hereditary Breast and Ovarian Cancer
- Noninvasive Biomarkers Advance Colorectal Cancer Risk Assessment
- Rapid Brush Biopsy Test Detects Oral Cancer in One Hour
- AI-Driven Blood Test Enhances Early Detection of Multiple Cancers
- Interpretable AI Tool Improves Prediction of Immunotherapy Response
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read more
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read morePathology
view channel
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read more
AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
Lung cancer is the leading cause of cancer-related death, and many patients require rapid genotyping to guide targeted therapy selection. Current workflows often rely on molecular tests that are costly,... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more




 Assay.jpg)



